Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials

tDCS for Late-Life Depression

NCT07657234
Recruiting
Conditions Late Life Depression (LLD), Depression -...
Phase PHASE1, PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to determine the effectiveness of Transcranial direct current stimulation (tDCS) therapy in the treatment of participants with Late-life depression (LLD). The study will evaluate feasibility, safety, and tolerability of high-dose (6mA) bilateral tDCS delivered as three daily sessions, 3 times a week, for 3 weeks in older adults (60 y/o and older) with late-life depression.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: High-intensity (6 mA) transcranial direct current stimulation (tDCS) — High-intensity (6 mA), spaced (three daily sessions, 3 times a week, for 3 weeks) transcranial direct current stimulation (tDCS) in older adults (60 y/o and over) with Late-Life Depression

Primary Outcomes

  • Treatment Tolerability (6 weeks)
  • Treatment Feasibility (6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2026-10
Completion: 2027-10
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Andre Russowsky Brunoni
Principal Investigators:
  • Andre Russowsky Brunoni, MD PhD (PRINCIPAL_INVESTIGATOR) - University of Texas Southwestern Medical Center
Contact Information
Study Contact:
Clinical Research Coordinator
214-645-2991
alexus.washington@utsouthwestern.edu
Andre Russowsky Brunoni, MD PhD
University of Texas Southwestern Medical Center
Interventions
  • Device: High-intensity (6 mA) transcranial direct current stimulation (tDCS) — High-intensity (6 mA), spaced (three daily sessions, 3 times a week, for 3 weeks) transcranial direct current stimulation (tDCS) in older adults (60 y/o and over) with Late-Life Depression
Study Locations (1 sites)
University of Texas Southwestern Medical Center, Dallas, Texas 75390 United States
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the following criteria: 1. age 60 years or older; 2. diagnosis of unipolar major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), confirmed by the Structured Clinical Interview for DSM-5 (SCID-5); 3. score of 16 or higher on the Quick Inventory of Depressive Symptomology-Clinician Rated (QIDS-C) at screening; 4. stable antidepressant regimen for at least four weeks prior to enrollment, if applicable; 5. willingness and capacity to provide informed consent; 6. Clinical Dementia Rating scale of 0 or 0.5. 7. availability of an informant who has sufficient knowledge of the participant's daily functioning as ascertained by the study team. Exclusion Criteria: Participants meeting any of the following criteria will be excluded: 1. contraindications to tDCS including metallic cranial implants, skin conditions at electrode sites (eczema, open wounds, burns, lesions), or history of adverse reaction to tDCS; 2. contraindications to magnetic resonance imaging (MRI) including pacemaker, cochlear implants, ferromagnetic implants, or claustrophobia; 3. depressive disorder due to a medical condition; 4. psychotic depression; 5. history of seizures or epilepsy; 6. bipolar disorder; 7. psychotic disorders; 8. severe personality disorder; 9. active substance use disorder within the past six months or history of substance induced mood or psychotic disorder; 10. neuromodulation treatment including electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), tDCS, or vagus nerve stimulation (VNS) within the past six months; 11. active suicidal ideation with plan or intent requiring a higher level of care; 12. concurrent use of medications that substantially lower seizure threshold; 13. pregnancy; 14. a clinically established diagnosis of dementia as reported in the participant's health record or scoring 1 or above on CDR; 15. medically unstable in the clinical opinion of the principal investigators.
Conditions Chronic Pain, Depression, Anxiety
Phase NA
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this research study is to refine customized in-app notifications in order to optimize users' experience with a mobile app called Wysa for Chronic Pain. This app is designed to support people who have chronic pain and who also experience symptoms of depression and/or anxiety. This version of the app is not currently available to the public. Eligible participants will be asked to download and use the Wysa for Chronic Pain study app for several weeks, and to use it as they normally would if they were not part of a research study. At the beginning and end of the study period, participants will be asked to complete brief surveys about their mood, pain, physical function, and sleep. Additionally, a few participants will be asked to share their experience with the study app at the end of the research study in a casual interview using a secure audio/video recorded call. Participating in the interview portion is optional.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Sequential Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Just-In-Time Adaptive Interventions (JITAIs) — JITAIs are digital interventions that aim to deliver support to a user when the person is most in need and receptive to the intervention. In this study, multiple JITAIs will be tested and refined through completion of an iterative series of randomized trials that are interspersed with qualitative participant interviews. The purpose of each JITAI under investigation is to improve engagement with the Wysa for Chronic Pain app.
  • Behavioral: Wysa for Chronic Pain — Wysa for Chronic Pain is an app-based digital mental health intervention that uses a behavioral activation framework and encourages users to work toward pain acceptance. The intervention also includes cognitive behavioral therapy, mindfulness, and sleep tools.

Primary Outcomes

  • Engagement (Each JITAI has a different target engagement time interval. e.g., varying from 24 hours to 7 days.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-02
Completion: 2026-12
Eligibility
Age: 45 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Collaborators: National Institute of Mental Health (NIMH), Duke University, Wysa
Principal Investigators:
  • Abby L. Cheng, MD, MPHS (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Adriana Martin
314-530-9023
azmartin@wustl.edu
Research Coordinator
314-747-8489
Interventions
  • Other: Just-In-Time Adaptive Interventions (JITAIs) — JITAIs are digital interventions that aim to deliver support to a user when the person is most in need and receptive to the intervention. In this study, multiple JITAIs will be tested and refined through completion of an iterative series of randomized trials that are interspersed with qualitative participant interviews. The purpose of each JITAI under investigation is to improve engagement with the Wysa for Chronic Pain app.
  • Behavioral: Wysa for Chronic Pain — Wysa for Chronic Pain is an app-based digital mental health intervention that uses a behavioral activation framework and encourages users to work toward pain acceptance. The intervention also includes cognitive behavioral therapy, mindfulness, and sleep tools.
Study Locations (1 sites)
Washington University in St. Louis School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Inclusion Criteria: * 45 years or older * At least moderately severe depression and/or anxiety symptoms (Patient Health Questionnaire-9 (PHQ-9) and/or Generalized Anxiety Disorder-7 (GAD-7) score ≥ 10) * Chronic pain (i.e., pain on most days or every day in the past three months) Exclusion Criteria: * Frequent active suicidal ideation * No access to a mobile device * Not living in the United States
Conditions Depression, Cancer, Adolescent, Young Ad...
Phase NA
Enrollment 208
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Our team has developed a digital intervention that aims to help adolescent and young adult cancer survivors (AYAs) manage symptoms of depression. This tool includes one psychoeducation component and four components that are based on evidence-based interventions for depression. The goal of this study is to test which component or combination of components meaningfully contribute to improvements in depressive symptoms among AYAs.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: AYA Survivors Coping and Emotional Needs Toolkit (ASCENT) — Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.

Primary Outcomes

  • Change in Depressive Symptoms during Intervention Period (Baseline to Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-25
Completion: 2027-03
Eligibility
Age: 15 Years and older
Sex: ALL
Volunteers: false
Enrollment: 208 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: East Carolina University
Collaborators: National Cancer Institute (NCI), Wake Forest University Health Sciences
Principal Investigators:
  • Karly M Murphy, PhD (PRINCIPAL_INVESTIGATOR) - East Carolina University
Contact Information
Study Contact:
AnneMarie Coffey, BS
252-328-6244
coffeya23@ecu.edu
Lane Williamson
williamsonla24@students.ecu.edu
AnneMarie Coffey, BS
252-328-6244
coffeya23@ecu.edu
East Carolina University
Interventions
  • Behavioral: AYA Survivors Coping and Emotional Needs Toolkit (ASCENT) — Participants will receive access to a digital depression self-management tool (ASCENT), which aims to help AYAs manage symptoms of depression post-treatment. All users will have access to the core tool which includes daily mood tracking and a psychoeducational module about cancer and depression. Depending on assigned condition, participants will also receive access to up to 4 intervention modules which have been adapted from existing evidence-based treatments for digital delivery to AYAs through a rigorous user-centered design process. Within each module there are 6 micro-lessons that include an educational video, a real story from an AYA that demonstrates the topic, multiple choice questions that ask the participant to apply the educational information to the AYA story, open-ended questions that ask the participant to apply the educational information to their own experience, and a practice activity in which they are asked to try out a relevant skill.
Study Locations (2 sites)
East Carolina University, Greenville, North Carolina 27858 United States
Wake Forest University, Winston-Salem, North Carolina 27109 United States
Eligibility Criteria
Inclusion Criteria: * Age at enrollment (adolescents 15-17, emerging adults 18-25, young adults 26-39) * Age at diagnosis (adolescents 12-17, emerging adults 15-25, young adults 15-39) * Time since completion of treatment: 1 month to 5 years * Language: Fluent in English (spoken and written) * Technology: Own smart phone with data plan Exclusion Criteria: * Mental Health: Current diagnosis of severe or persistent mental illness * Suicidality: Severe suicidal ideation (including plan and intent)
Conditions Major Depressive Disorder, MDD
Phase PHASE3
Enrollment 145
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if drug Rosuvastatin 10 mg works to treat MDD in adults. It will also learn about the safety of Rosuvastatin 10 mg .The main questions it aims to answer are: Does Rusovastatin lower the score of The Montgomery Asberg Depression Rating Scale (MADRS) among adult participants with Major Depression Disorder ( MDD )? What medical problems do participants have when taking drug ABC? Participants will: Take Rosuvastatin 10 mg every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Report any side effects for Rosuvastatin 10 mg and reassess the severity of depression using The Montgomery Asberg Depression Rating Scale (MADRS)

Design

Study type: Interventional Phases: Phase3 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Rosuvastatin 10 mg tablet. — The dose of rosuvastatin was derived from literature describing the doses at which the agents' targeted actions are effective and safe. The 10- mg rosuvastatin dose reflects the lowest prescribed therapeutic dose A serum cholesterol level will be drawn from the whole participants and sent to the central laboratories of El-Demerdash hospital at baseline and at week 12. At each visit, participants will be requested to return all unused investigational products. Adherence to medication will be assessed by a pill count.
  • Drug: Sertraline Pill — Both control and intervention group will receive the sertraline as a standard therapy

Primary Outcomes

  • Severity of depression among Participants with MDD as Assessed by MADRS scale (3 months (12 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-10-01
Completion: 2025-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: true
Enrollment: 145 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ain Shams University
Contact Information
Study Contact:
Silvana Nader
01226058776
Slvana_nader@med.asu.edu.eg
Silvana Nader
01226058776
Slvana_nader@med.asu.edu.eg
El demerdash hospital
Interventions
  • Drug: Rosuvastatin 10 mg tablet. — The dose of rosuvastatin was derived from literature describing the doses at which the agents' targeted actions are effective and safe. The 10- mg rosuvastatin dose reflects the lowest prescribed therapeutic dose A serum cholesterol level will be drawn from the whole participants and sent to the central laboratories of El-Demerdash hospital at baseline and at week 12. At each visit, participants will be requested to return all unused investigational products. Adherence to medication will be assessed by a pill count.
  • Drug: Sertraline Pill — Both control and intervention group will receive the sertraline as a standard therapy
Study Locations (1 sites)
El demerdash hospital, Cairo, Al Abbasia +02 Egypt
Eligibility Criteria
Inclusion Criteria: * aged between 20 and 45 years; * diagnosis of current MDD, verified using the Structured Clinical Interview for DSM-IV Axis I Disorders, patient version (SCID-I/P); * The Montgomery Asberg Depression Rating Scale (MADRS) score of 7 to 34, indicating mild to moderate depression; * the ability to give informed consent and to comply with standard procedures; * Males and females; and * Stable pharmacological treatment for at least 2 weeks prior to enrolment (changes to medication dose or frequency of therapy excepted) if currently being treated. Exclusion Criteria: * lifetime or current SCID-I/P diagnosis of a psychotic disorder; * lifetime SCID-I/P diagnosis of bipolar I or II disorder or alcohol dependence; * acute or unstable systemic medical disorder; * inability to comply with the requirements of informed consent or the study protocol; * history of intolerance or allergy to study medications; * Current pregnancy or breast feeding; * Current regular use of statins, corticosteroids, or any other immunomodulatory agents; and * Females on Contraception.
Conditions Major Depressive Disorder (MDD)
Phase PHASE2
Enrollment 118
Locations 23 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

In this study, researchers will learn more about a study drug called DT-101 in participants with Major Depressive Disorder (MDD), a form of depression. The goal of this clinical trial is to learn if DT-101 can treat depression in adults. The effect of DT-101 will be compared to placebo. A placebo looks the drug but contains no medicine. Subjects will attend the clinic for complete general health checks and to complete questionnaires.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: DT-101 — DT-101
  • Drug: Placebo — Placebo

Primary Outcomes

  • Change from baseline in total Montgomery Åsberg depression rating scale (MADRS) score, at Day 56 (from enrolment to day 56)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-14
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 118 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Draig Therapeutics Ltd
Contact Information
Study Contact:
Aeron-1 Clinical Team
+44(0)2920028450
info@draigtherapeutics.com
Draig Clinical Site
+44(0)2920028450
info@draigtherapeutics.com
Draig Clinical Site
Draig Clinical Site
+44(0)2920028450
info@draigtherapeutics.com
Draig Clinical Site
Interventions
  • Drug: DT-101 — DT-101
  • Drug: Placebo — Placebo
Study Locations (23 sites)
Draig Clinical Site, Phoenix, Arizona 85013 United States
Draig Clinical Site, Little Rock, Arkansas 72211 United States
Draig Clinical Site, Bellflower, California 90706 United States
Draig Clinical Site, Costa Mesa, California 92626 United States
Draig Clinical Site, Lafayette, California 94549 United States
Draig Clinical Site, Hialeah, Florida 33016 United States
Draig Clinical Site, Orlando, Florida 32803 United States
Draig Clinical Site, Orlando, Florida 32807 United States
Draig Clinical Site, Tampa, Florida 33607 United States
Draig Clinical Site, Tampa, Florida 33613 United States
Eligibility Criteria
Inclusion Criteria: * The participant is able to read, understand and communicate in the local language used at the study site, and is willing to provide written informed consent * Male or female (assigned at birth, inclusive of all gender identities) participant must be 18 to 75 years of age, inclusive at the time of signing the informed consent. * Has recurrent depression (defined as at least one prior episode excluding the current one), as diagnosed by DSM 5-TR (Diagnostic and Statistical Manual of Mental Disorders, 2022). Exclusion Criteria: * Pregnant or breastfeeding or plans to become pregnant during the study. * Unstable medical condition or unstable chronic disease. * Significant neurological abnormality. * History of moderate or severe alcohol or drug use disorder as per DSM-5-TR in the 6 months prior to Screening. * History of seizure. * In the investigator's opinion, the participant is not capable of adhering to the protocol requirements.
Conditions PTSD - Post Traumatic Stress Disorder, P...
Phase NA
Enrollment 640
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Addiction and trauma exposure are common among the 5.5 million people (1 in 47 adults) in the U.S. who are in prison or under supervision. About 85% of people in prison have a substance use disorder or are there for a drug-related crime, and many have experienced serious trauma before being incarcerated. Posttraumatic stress symptoms (PTSS) are often a result of trauma and are linked to more severe drug use, higher rates of relapse, and increased crime. PTSS and substance use disorder (SUD) each raise the chances of new arrests for people who are justice-involved, showing that addressing trauma and addiction could help reduce repeat offenses and the costs of incarceration. However, treatments for PTSS are rarely available in prisons, and there is little research on whether providing therapy for PTSS in prison can lower drug use, PTSS, or crime after release. The goal of this clinical trial is to see if trauma-focused group therapy (CPT) provided while in prison, can help people after release from prison. The therapy has been adapted for use in prisons (CPT-CJ) and will be compared to trauma focused therapy delivered via a self-help workbook This study will: * test whether a trauma-focused group therapy (CPT-CJ) can reduce post-incarceration drug and alcohol use, mental health issues, and drug-related crime, compared to trauma-focused self-help, * evaluate a strategy called implementation facilitation, which helps support the use of this therapy in prisons, and * measure the cost of the therapies and support strategies to help plan for future expansion. Incarcerated participants (N = 640; 50% female) will be enrolled from \~10 prisons in \~5 states, ensuring variability in population and setting characteristics. They will: * take surveys and answer questions up to 5 times (before starting treatment, right after getting treatment, right before leaving prison, 3 months after leaving prison and 6 months after leaving prison) * complete CPT group therapy or self-help therapy * provide urine samples 3 months and 6 months after leaving prison Prison stakeholders (e.g., prison staff, prison leadership, governmental officials; N = \~15 per site) who will be purposively sampled based on their role in CPT-CJ implementation will also participate in some surveys.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Group Cognitive Processing Therapy (CPT) — Participants in CPT group therapy will learn about trauma and how to change upsetting thoughts related to it. Participants will attend up to a total of 12 sessions held 1-2x/week for 90 minutes. No more than 10 participants will be in a group. In this study, CPT provided is a version that was adapted for prisons.
  • Behavioral: Control Group Individual trauma focused self-help via workbook — The self-help therapy is a therapy that people do on their own using a workbook. By reading and doing practice assignments in the workbook, people can learn skills to recover from trauma.

Primary Outcomes

  • Drug Use Frequency (Count) (3- and 6-month post-release from prison)
  • Drug use (Binary) (3- and 6-month post-release from prison)
  • Posttraumatic Stress Symptom Severity (Sum) (Pre-treatment assessments will be ~2 wks before tx starts; post-treatment will be ~2 wks after tx ends; pre-release will be ~3 days before release; post-release follow-ups will be 3- and 6-mo after prison exist)
  • Treatment fidelity (ratio) (Fidelity assessments will be done during the active treatment period which can be as short as 6 weeks to as long as 3 months for participants. The active treatment period is expected to span 1.5 years at each site.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-07
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 640 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Arkansas
Collaborators: National Institute on Drug Abuse (NIDA)
Principal Investigators:
  • Melissa J Zielinski, PhD (PRINCIPAL_INVESTIGATOR) - University of Arkansas
Contact Information
Study Contact:
Melissa J Zielinski, PhD
501-526-8229
MJZielinski@uams.edu
Mollee K Smith Steely, PhD
501-320-7271
MKSteelysmith@uams.edu
Melissa J Zielinski, PhD
501-526-8229
MJZielinski@uams.edu
University of Arkansas for Medical Sciences
Interventions
  • Behavioral: Group Cognitive Processing Therapy (CPT) — Participants in CPT group therapy will learn about trauma and how to change upsetting thoughts related to it. Participants will attend up to a total of 12 sessions held 1-2x/week for 90 minutes. No more than 10 participants will be in a group. In this study, CPT provided is a version that was adapted for prisons.
  • Behavioral: Control Group Individual trauma focused self-help via workbook — The self-help therapy is a therapy that people do on their own using a workbook. By reading and doing practice assignments in the workbook, people can learn skills to recover from trauma.
Study Locations (6 sites)
University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
Northeast Arkansas Community Corrections Center (NEACC), Osceola, Arkansas 72370 United States
Southwest Arkansas Community Correction Center, Texarkana, Arkansas 71854 United States
East Central Arkansas Community Correction Center, West Memphis, Arkansas 72301 United States
North Dakota State Penitentiary (NDSP), Bismarck, North Dakota 58501 United States
Heart River Correctional Center (HRCC), Bismarck, North Dakota 58502 United States
Eligibility Criteria
Inclusion Criteria: * 18 years of age or older * Able to understand and speak English * Able to give informed consent * All items listed in "Inclusion criteria for all participants" * Be currently incarcerated in one of the prisons that have partnered as study sites * Have met criteria for a drug use disorder in the year prior to their current incarceration (≥ 2 symptoms on a DSM-5 drug use disorder checklist) * Have used drugs in the 30 days prior to their current incarceration * Have a history of traumatic event exposure * Endorse clinically significant posttraumatic stress symptoms (score ≥ 4 on the Primary Care PTSD Screen for DSM-5; PC-PTSD-5) * Expect to be incarcerated for at least long enough to complete CPT-CJ as it is being implemented at the particular site (i.e., anticipated to be \~3 months, but will depend on dates associated with next available intervention group) * Expect to be released from prison within 12 months following the end of treatment (i.e., within \~15 months of the pre-treatment assessment) * Willing to consent to randomization to treatment condition Exclusion criteria for prisoners (additional requirements assessed during pre-treatment assessments or indicated by prison staff; will result in being withdrawn from the study prior to randomization by the PI): * Unable to provide any locator information for post-release assessments * Determined to be releasing sooner than would allow the individual to complete CPT-CJ * Determined to have an unavoidable scheduling conflict or facility restriction (e.g., disciplinary, medical) that would prevent participation in CPT-CJ. Of note, if the scheduling conflict or facility restriction is expected to resolve following the next round of randomization at the study site, the participant may be put on "hold for next round" status rather than withdrawn unless other exclusionary criteria would be met by that time (e.g., release).
Conditions Cirrhosis, Liver, Portal Hypertension, A...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

How to construct a novel, non-invasive, accurate, and convenient method to achieve prediction of hepatic venous pressure gradient (HVPG) is an important general problem in the management of portal hypertension in cirrhosis or advanced chronic liver disease. We plan to investigate the ability of three demensional-magnetic resonance elastography (3D-MRE) to establish a risk stratification system and perform tailored management for portal hypertension in cirrhosis or advanced chronic liver disease.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: 3D-MRE — All imaging studies were performed by using a 3.0-T MRI system ( GE Healthcare) with a phasedarray body coil.
  • Device: HVPG — HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.

Primary Outcomes

  • Accuracy of the features of 3D-MRE for assessing portal hypertension in cirrhosis. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-08-16
Completion: 2026-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shengjing Hospital
Collaborators: Zhongda Hospital
Principal Investigators:
  • Yu Shi, Prof. (PRINCIPAL_INVESTIGATOR) - Shengjing Hospital
  • Shenghong Ju, Prof. (PRINCIPAL_INVESTIGATOR) - Zhongda Hospital
  • Xiaolong Qi, Prof. (PRINCIPAL_INVESTIGATOR) - Zhongda Hospital
Contact Information
Study Contact:
Yifei Huang, M.D.
+86 158 0000 4518
huangyf1995@foxmail.com
Yu Shi, Prof.
+86 189 4025 9980
18940259980@163.com
Yifei Huang, MD
huangyf1995@foxmail.com
Shengjing Hospital
Interventions
  • Device: 3D-MRE — All imaging studies were performed by using a 3.0-T MRI system ( GE Healthcare) with a phasedarray body coil.
  • Device: HVPG — HVPG measurements are performed by well-trained interventional radiologists in accordance with standard operating procedures.
Study Locations (1 sites)
Shengjing Hospital, Shenyang, Liaoning 210000 China
Eligibility Criteria
Inclusion criteria were: (1) ≥18 years; (2) written informed consent; (3) confirmed ACLD of any liver disease etiology; (4) clinically indicated for HVPG measurement, with 3D-MRE performed within one month prior. Exclusion criteria were: (1) hepatic or extrahepatic malignancies, or large hepatic or splenic focal diseases affecting MRE measurement; (2) MR or HVPG contraindications; (3) prior liver or splenic surgery affecting MRE measurement; (4) treatment with nonselective β-blockers (NSBB) between MRE and HVPG measurements; (5) invalid or unreliable HVPG or MRE results and (6) biliary obstruction or dilation on MR images.
Conditions Glaucoma
Phase PHASE3
Enrollment 510
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: Gen 2 Travoprost Intracameral Implant — Travoprost
  • Drug: Timolol eye drops 0.5% — Timolol 0.5%
  • Procedure: Sham Procedure — Sham implant administration
  • Other: placebo eye drops — Artificial Tears

Primary Outcomes

  • Intraocular pressure (IOP) (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-02-17
Completion: 2032-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 510 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Glaukos Corporation
Contact Information
Study Contact:
Study Director
949-739-8749
ClinicalResearch@glaukos.com
Luis Vargas, MD
949-739-8749
ClinicalResearch@glaukos.com
Glaukos Investigative Site
Interventions
  • Drug: Gen 2 Travoprost Intracameral Implant — Travoprost
  • Drug: Timolol eye drops 0.5% — Timolol 0.5%
  • Procedure: Sham Procedure — Sham implant administration
  • Other: placebo eye drops — Artificial Tears
Study Locations (1 sites)
Glaukos Investigative Site, Dothan, Alabama 36301 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Ocular Hypertension or Open-Angle Glaucoma in the study eye Exclusion Criteria: * Prior incisional glaucoma surgery in the study eye * Prior argon laser trabeculoplasty (ALT) in the study eye * Prior minimally invasive glaucoma (MIGS) surgery in the study eye
Conditions Metastatic Colorectal Cancer (Mcrc), Int...
Phase PHASE2
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Background: One way to treat liver cancer is to deliver chemotherapy drugs only to the liver (and not to the whole body). Researchers want to see if adding the drug PDS01ADC can improve the treatment. The drug triggers the immune system to fight cancer.\<TAB\> Objective: To see if treatment with HAIPs to deliver liver-directed FUDR and Dexamethasone chemotherapy in combination with PDS01ADC is effective for certain cancers. Eligibility: People aged 18 and older who have cancer of the bile ducts that is only in the liver, or colorectal cancer that has spread to the liver, or cancer of the adrenal glands that has spread to the liver, who are also receiving or planning to receive standard systemic chemotherapy for their disease. Design: Participants will be screened with: Medical history Physical exam Blood tests Pregnancy test (if needed) Tumor biopsy (if needed) Electrocardiogram Computed tomography (CT) scans Participants will have an abdominal operation. A catheter will be placed into an artery that feeds blood to the liver. The catheter will then be attached to the HAIP. The HAIP will lay under the skin on the left side of the abdomen. All participants will have liver-directed FUDR and Dexamethasone chemotherapy drugs or heparin with saline infused into the HAIP every 2 weeks. PDS01ADC will be injected under the skin every 4 weeks. They will receive this treatment until their cancer gets worse or they have bad side effects. Participants will also receive standard systemic chemotherapy for their disease, assigned based on diagnosis, through an IV by their medical oncologist (at NIH or by a local provider) every 2 weeks. Participants will have 2 study visits at NIH each month. They will have CT scans every 8 weeks. At visits, they will repeat some screening tests. Participants will have a follow-up visit 1 month after treatment ends. Then they will be contacted every 6 months for 5 years.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Dexamethasone — HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Dexamethasone: (1 mg/day X pump volume / pump flow rate)
  • Drug: PDS01ADC — PDS01ADC will be administered by subcutaneous injection on Day 15 of every cycle. Cycle 1 at 12 mcg/kg; Cycle 2 reduced to 8 mcg/kg with the addition of systemic chemotherapy, to continue for further cycles. Note: any dose reduction in FUDR = 50% due to liver enzyme elevations means that the dose of PDS01ADC will be reduced to 4 mcg/kg.
  • Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP) — Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.
  • Drug: Floxuridine — HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL \[pump volume\] / Pump Flow Rate)

Primary Outcomes

  • Determine overall response rates (baseline, every 8 weeks while on treatment, and 4-8 weeks following initial documentation of objective response; an additional scan is performed at Week 12.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-10-24
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Cancer Institute (NCI)
Principal Investigators:
  • Jonathan M Hernandez, M.D. (PRINCIPAL_INVESTIGATOR) - National Cancer Institute (NCI)
Contact Information
Study Contact:
Kathleen M Smith, R.N.
(240) 858-3531
kathleen.smith3@nih.gov
Jonathan M Hernandez, M.D.
(240) 760-6072
jonathan.hernandez@nih.gov
For more information at the NIH Clinical Center contact National Cancer Institute Referral Office
888-624-1937
National Institutes of Health Clinical Center
Interventions
  • Drug: Dexamethasone — HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Dexamethasone: (1 mg/day X pump volume / pump flow rate)
  • Drug: PDS01ADC — PDS01ADC will be administered by subcutaneous injection on Day 15 of every cycle. Cycle 1 at 12 mcg/kg; Cycle 2 reduced to 8 mcg/kg with the addition of systemic chemotherapy, to continue for further cycles. Note: any dose reduction in FUDR = 50% due to liver enzyme elevations means that the dose of PDS01ADC will be reduced to 4 mcg/kg.
  • Device: Intera 3000 Hepatic Artery Infusion Pump (HAIP) — Intera 3000 HAIP will be filled with mixture of Floxuridine and Dexamethasone in 25,000 units heparin/saline (Heparin + 0.9% Sodium Chloride) on Day 1; Days 1-14 of every cycle pump will perfuse drugs to liver. On Day 15 of each cycle, the pump will be emptied and filled with 30,000 units heparin/saline (Heparin + 0.9% Sodium Chloride); Days 15-28 of every cycle will perfuse heparin/saline to liver.
  • Drug: Floxuridine — HAIP FUDR and Dexamethasone treatment on D1 of every cycle. Floxuridine: (0.12 mg/kg x ideal average body weight in kg X 30 mL \[pump volume\] / Pump Flow Rate)
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: Inclusion Criteria- All Cohorts * Participants must have a documented diagnosis of one of the following cancers: * Metastatic colorectal cancer (mCRC) * Intrahepatic cholangiocarcinoma (ICC) * Adrenocortical carcinoma (ACC) with liver dominant disease * Participants must have an identified medical oncologist who has recommended and is planning to oversee treatment with one of the following standard chemotherapy regimens (based on disease type) not to begin sooner than 28 days after initiation of study-directed HAIP intervention: * mCRC: FOLFOX or FOLFIRI * ICC: GemOx or FOLFOX * ACC: GemOx * Age \>= 18 years. * Negative serum or urine pregnancy test at screening for individuals of childbearing potential (IOCBP). NOTE: IOCBP is defined as any individual who has experienced menarche and who has not undergone successful surgical sterilization or who is not postmenopausal. IOCBP must have a negative pregnancy test (HCG blood or urine) during screening. * All participants (regardless of childbearing potential) must agree to use highly effective contraception prior to study entry, for the duration of study participation, and for 3 months after completion of study treatment for those able to father a child or 6 months after completion of study treatment for those of child-bearing potential (i.e., IOCBP). Highly effective birth control (failure rate of less than 1%), e.g., intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner and sexual abstinence. Note: The use of condoms by participants who are able to get other individuals pregnant is required unless the partner of childbearing potential is permanently sterile. * Nursing (including breastfeeding) participants must agree to discontinue nursing. * Arterial anatomy on CT angiogram or CT chest, abdomen and pelvis multiphase (i.e., CT C/A/P multiphase) amenable to placement of the HAIP. * Participant must sign the informed consent form to participate in this study. * HIV-positive participants may be considered for this study only if they have an undetectable viral load. * Participants must agree to co-enroll on the Surgical Oncology Program s tissue collection protocol 13C0176, "Tumor, Normal Tissue and Specimens from Patients Undergoing Evaluation or Surgical Resection of Solid Tumors". * Participant's liver metastases must not be amenable to resection/ablation to No Evidence of Disease (NED) in one stage. Inclusion Criteria-Metastatic Colorectal Carcinoma * Participants must have histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma metastatic to the liver (Cohort 1). * Participants must have measurable liver metastatic disease. * Participants must have received 1st line systemic chemotherapy. * ECOG performance status \<= 1. * Participants must have adequate organ and marrow function as defined below: * leukocytes \> 3,000/mcL * absolute neutrophil count \> 1,500/mcL * platelets \> 90,000/mcL * hemoglobin \> 8 g/dL * total bilirubin \< 1.5 X institutional upper limit of normal * AST(SGOT)/ALT(SGPT) \< 2.5 X institutional upper limit of normal * creatinine within normal institutional limits OR eGFR within normal as predicted by the CKD-EPI equation \> 60 mL/min/1.73 m2. Inclusion Criteria-Intrahepatic Cholangiocarcinoma * Participants must have histologically or cytologically confirmed diagnosis of intrahepatic cholangiocarcinoma confined to the liver (Cohort 2). Archival tumor sample may be used but if archival tissue is not available or is not adequate, tissue biopsy will be required. * Clinical or radiographic evidence of metastatic disease to regional (porta hepatis) lymph nodes will be allowed, provided it is amenable to resection. * Participants must have radiographically measurable disease. * Disease must be considered unresectable at the time of preoperative evaluation. * Participants must have received 1st line systemic chemotherapy. * ECOG performance status \<=1. * Participants must have adequate organ and marrow function as defined below: * leukocytes \>= 2,000/ mm\^3 * absolute neutrophil count \> 1,500/mcL * platelets \>= 75,000/ mm\^3 * hemoglobin \> 8 g/dL * total bilirubin \< 1.5 mg/dl * creatinine \<= 1.5 mg/dl Inclusion Criteria-Adrenocortical Carcinoma * Participants must have histologically or cytologically confirmed diagnosis of adrenocortical carcinoma (ACC), also referred to as "adrenocortical cancer". * Participants must have received at least one line of systemic chemotherapy. * Participants must have measurable liver metastatic disease. * ECOG performance status \<= 1. * Participants must have adequate organ and marrow function as defined below: * leukocytes \> 3,000/mcL * absolute neutrophil count \> 1,500/mcL * platelets \> 90,000/mcL * hemoglobin \> 8 g/dL * total bilirubin \< 1.5 X institutional upper limit of normal * AST(SGOT)/ALT(SGPT) \< 3 X institutional upper limit of normal * creatinine \< 2 X institutional upper limit of normal EXCLUSION CRITERIA: Exclusion Criteria- All Cohorts Participants who are receiving any other investigational agents. * Participants who have previously received rIL-12. * Participants with active autoimmune diseases, that might deteriorate when receiving an immunostimulatory agent with the exceptions: * diabetes type I, vitiligo, alopecia, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible; * participants requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses \<= 10 mg of prednisone or equivalent per day; * administration of steroids for other conditions through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) is eligible. * History of organ transplant, except for transplants that do not require immunosuppression. * History of or active inflammatory bowel disease (e.g., Crohn s disease, ulcerative colitis). * Known hypersensitivity or allergic reactions attributed to any compounds of similar chemical or biologic composition to the study medication, such as recombinant IL-12 or other monoclonal antibodies and history of allergic reactions attributed to compounds of similar chemical composition to FUDR or heparin. * Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke \< 6 months prior to enrollment, myocardial infarction \< 6 months prior to enrollment, unstable angina, congestive heart failure (\>= NYHA III) or serious cardiac arrhythmia requiring medication. * All conditions associated with significant necrosis of nontumor-bearing tissues. * Esophageal or gastroduodenal ulcers \< 6 months prior to treatment. * Active ischemic bowel disease. * Psychiatric illness/social situations that would limit compliance with study requirements. * Active concurrent malignancies within the last five years other than colorectal primary except basal cell skin carcinoma and thyroid carcinoma. * Prior radiation to liver. * Participants with active Hepatitis B or C infection. * Significant acute or chronic infections (i.e., tuberculosis) history of exposure or history of positive tuberculosis test; plus, presence of clinical symptoms, physical or radiographic findings). * Any condition, including the presence of laboratory abnormalities and/or insufficient normal liver parenchyma, which places the participant at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study. Exclusion Criteria-Metastatic Colorectal Carcinoma -Participants with incontrovertible radiographic evidence of disease outside of the colon/rectum (primary) and liver given unlikelihood of benefit from liver-directed therapy. Note: Lung lesions seen on CT do not always represent metastases. They are very h
Conditions Screening
Phase NA
Enrollment 2000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized trial to assess whether offering a financial incentive will improve the response rate to a telephone survey. Three incentive approaches will be compared: a $5 gift card, entry into a monthly $100 drawing, or no incentive.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: None

Interventions / Regimen

  • Other: $5 gift card — A $5 gift card is offered as an incentive to participation in the 3-month survey call.
  • Other: $100 monthly drawing — Entry into monthly drawing for $100 gift card is offered as an incentive to participation in the 3-month survey call.

Primary Outcomes

  • Survey completion (One month after the outreach call is completed)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-01
Completion: 2029-09-30
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, San Francisco
Collaborators: Centers for Disease Control and Prevention
Principal Investigators:
  • Jeremy D Keenan, MD MPH (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
  • Yvonne Ou, MD (PRINCIPAL_INVESTIGATOR) - University of California, San Francisco
Contact Information
Study Contact:
Dionna Wittberg, MPH
13306083016
dionna.wittberg@ucsf.edu
Jeremy D Keenan, MD MPH
jeremy.keenan@ucsf.edu
Angela Shahbazian, OD, FAAO
510-835-9610
a.shahbazian@berkeley.edu
Baywell Health
Interventions
  • Other: $5 gift card — A $5 gift card is offered as an incentive to participation in the 3-month survey call.
  • Other: $100 monthly drawing — Entry into monthly drawing for $100 gift card is offered as an incentive to participation in the 3-month survey call.
Study Locations (2 sites)
Baywell Health, Oakland, California 94607 United States
University of California, San Francisco, San Francisco, California 94158 United States
Eligibility Criteria
Inclusion Criteria: \- Participating in GSEARCH trial Exclusion Criteria: \- Patients without a valid phone number
Conditions Eisenmenger Syndrome, Pulmonary Arterial...
Phase PHASE4
Enrollment 36
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

What is this study about? This study will test whether adding sotatercept to usual medicines for pulmonary arterial hypertension (PAH) can help adults who have PAH due to unrepaired congenital heart defects (atrial or ventricular septal defect, or patent ductus arteriosus), including Eisenmenger syndrome. These conditions often cause long-standing changes in the lung blood vessels and low oxygen levels. Who can join? About 36 adults (age ≥18 years) in Japan whose PAH has not improved enough with pulmonary vasodilators may join. People with very severe symptoms (WHO class IV) or other serious illnesses will not be enrolled. What will happen if I join? Participants will be randomly assigned (like a coin flip, in a 2:1 ratio) to: Sotatercept + vasodilator-based PAH care, or vasodilator-based PAH care alone. The study lasts 24 weeks. Those who receive sotatercept will have injections every 3 weeks. All participants will have clinic visits and tests at the start, week 12, and week 24, including a 6-minute walk test (how far you can walk in 6 minutes), blood tests, questionnaires, and other heart-lung assessments used in routine PAH care. What are the possible benefits? Sotatercept improved exercise capacity and heart-lung measures in other PAH studies, but people with unrepaired heart defects were not included. This study may or may not help you directly, but it may help doctors learn how to use sotatercept safely in this group. What are the possible risks? Side effects seen with sotatercept include increase in haemoglobin, low platelets, nosebleeds, telangiectasia (small dilated blood vessels), bleeding, and blood clots. People with Eisenmenger syndrome can have both bleeding (for example, haemoptysis) and clotting risks. The study will check complete blood counts (CBC) regularly and adjust or pause dosing using label-based rules. Other risks are those of standard PAH care and blood tests. Time and location The study is conducted at multiple hospitals in Japan. Study participation lasts about 6 months. Costs and payments The study drug and study-specific tests will be provided at no cost. Usual medical care not required by the study will follow each hospital's standard billing. There is no required payment to join. Any travel reimbursement or stipends will follow site policy. Privacy Your information will be kept confidential. Results will be shared in journals and at meetings without using your name. Who to contact If you are interested or have questions, please contact the study team at the participating hospital.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sotatercept — Sotatercept will be administered subcutaneously every 3 weeks for 24 weeks (total 8 injections): 0.3 mg/kg lead-in at Visit 1, then 0.7 mg/kg from Visit 2 if safety criteria are met. Dose holds/reductions follow label-concordant rules based on complete blood count (CBC) prior to each dose (e.g., hemoglobin rise \>4.0 g/dL from baseline; or \>2.0 g/dL from the previous dose and above ULN; or \>2.0 g/dL above ULN; and platelet count \<50,000/µL). Participants continue stable background PAH therapy (endothelin, nitric-oxide, prostacyclin pathways) per protocol; initiation or up-titration of PAH drugs during the 24-week treatment period is generally not permitted unless clinically mandated for safety and recorded as a protocol deviation.
  • Drug: vasodilator-based PAH therapy — Participants receive no sotatercept. They continue site-standard, stable PAH therapy for 24 weeks (endothelin receptor antagonist, PDE5 inhibitor/riociguat, and/or prostacyclin class as clinically indicated). Changes to background therapy are discouraged during the 24-week period unless required for safety; any changes are captured for analysis. The same visit schedule and assessments (e.g., 6-minute walk test, biomarkers, clinical events) apply as in the sotatercept arm.

Primary Outcomes

  • Change in 6-minute walk distance at 24 weeks from baseline (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-10-07
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kazuya Hosokawa
Contact Information
Study Contact:
Kazuya Hosokawa, MD, PhD
+81-92-642-5360
hosokawa.kazuya.712@m.kyushu-u.ac.jp
Keimei Yoshida, MD, PhD
yoshida.keimei.713@m.kyushu-u.ac.jp
Kazuya Hosokawa
+81-92-642-1151
hosokawa.kazuya.712@m.kyushu-u.ac.jp
Kyushu University Hospital
Interventions
  • Drug: Sotatercept — Sotatercept will be administered subcutaneously every 3 weeks for 24 weeks (total 8 injections): 0.3 mg/kg lead-in at Visit 1, then 0.7 mg/kg from Visit 2 if safety criteria are met. Dose holds/reductions follow label-concordant rules based on complete blood count (CBC) prior to each dose (e.g., hemoglobin rise \>4.0 g/dL from baseline; or \>2.0 g/dL from the previous dose and above ULN; or \>2.0 g/dL above ULN; and platelet count \<50,000/µL). Participants continue stable background PAH therapy (endothelin, nitric-oxide, prostacyclin pathways) per protocol; initiation or up-titration of PAH drugs during the 24-week treatment period is generally not permitted unless clinically mandated for safety and recorded as a protocol deviation.
  • Drug: vasodilator-based PAH therapy — Participants receive no sotatercept. They continue site-standard, stable PAH therapy for 24 weeks (endothelin receptor antagonist, PDE5 inhibitor/riociguat, and/or prostacyclin class as clinically indicated). Changes to background therapy are discouraged during the 24-week period unless required for safety; any changes are captured for analysis. The same visit schedule and assessments (e.g., 6-minute walk test, biomarkers, clinical events) apply as in the sotatercept arm.
Study Locations (10 sites)
Kyushu University Hospital, Fukuoka, Not Required For This Country 8150014 Japan
The Second Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan
Division of Cardiovascular Medicine, Kobe University Hospital, Kobe, Japan
Department of Cardiovascular Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Department of Cardiology, Nagoya University Hospital, Nagoya, Japan
Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
Department of Cardiology, Keio University School of Medicine, Tokyo, Japan
Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo, Japan
Division of Cardiovascular Medicine, Department of Internal Medicine, Showa University Graduate School of Medicine, Tokyo, Japan
Eligibility Criteria
Inclusion Criteria: * adults (≥18 years) * unrepaired ASD, VSD or PDA * ≥90 days of pulmonary vasodilator therapy; and either (i) pulmonary vascular resistance (PVR) ≥5 Wood units and mean pulmonary arterial pressure (mPAP) \> 20 mm Hg on right heart catheterization within 180 days, or (ii) echocardiographic tricuspid regurgitation velocity \>3.4 m/s with right-to-left/bidirectional shunt plus resting SpO₂ ≤92% consistent with cyanosis * baseline 6MWD ≥100 m * ability to complete questionnaires Exclusion Criteria: * WHO functional class IV; other unrepaired intracardiac shunts * severe renal/hepatic/parenchymal lung disease or LVEF \<40% * prior sotatercept use * contraindication to sotatercept per label * investigator-judged unsuitability
Conditions Hypertension
Phase PHASE4
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Study design: Investigator initiated, single center The study is aimed 1\) To investigate the blood pressure (BP) change to renal nerve stimulation(RNS), and subsequently perform a renal denervation(RDN) procedure 1\) to verify the cutoff value (RNS-induced systolic BP change \<20 mmHg in post-RDN patients) could be a useful clinical endpoint in RDN therapy, and test the hypothesis that intense RDN could improve the efficacy of RDN.

Design

Study type: Interventional Phases: Phase4 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: nerve stimulation guided renal denervation procedure — RNS-in

Primary Outcomes

  • arterial blood pressure response (during procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2022-06-24
Completion: 2027-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Contact Information
Study Contact:
Hui-Chun Huang, M.D
886-23123456
hchuangster@ntuh.gov.tw
National Taiwan University Hospital
Tzung-Dau Wang, PHD
886-23123456
tdwang@ntu.edu.tw
National Taiwan University Hospital
Interventions
  • Procedure: nerve stimulation guided renal denervation procedure — RNS-in
Study Locations (1 sites)
National Taiwan University Hospital, Taipei, 100 Taiwan
Eligibility Criteria
Inclusion Criteria: Patients with hypertension (HTN), including 1. 24-hour ambulatory blood pressure \>130/ 80 mmHg 2. Age 20-80 years 3. Glomerular filtration rate \>45 mL/min Exclusion Criteria: 1. Unsuitable renal artery anatomy computed tomographic angiography (main renal artery lumen diameter ≤3 mm or a total length \<20 mm of the main arteries). 2. untreated secondary HTN, including hyperaldosteronism, pheochromocytoma, renal artery stenosis(\>50% stenosis)